sector medic suppli devic
coverag buy
messag initi coverag buy rate pt
see good stori pois get even better pipelin matur
manag execut oper plan model call sale growth
feedback recent doc patient survey suggest
well posit take insulin pump share go forward time question
competit price loom larg continu glucos monitor cgm
side diabet market see benign competit condit pump
view omnipod differenti technolog within insulin
pump market offer signific advantag tradit durabl pump term
eas use comfort conveni compani uniqu approach allow
carv meaning share posit year sinc launch believ
recent put togeth piec necessari fulli leverag omnipod
commerci potenti competit dynam within pump market shift
favor well follow recent exit see posit sustain
top line growth next year view growth outlook least
partial reflect stock recent run past month vs
russel believ continu execut steadi cadenc pipelin
oper catalyst next month scarciti compar growth
stori across small-cap med-tech univers drive continu out-performance
omnipod novel form factor earn high mark diabet
endocrinologist commun tubeless dispos design offer signific
advantag conveni qualiti life perspect reduc up-front cost
pump adopt may even confer clinic benefit term greater dose accuraci
recent survey type diabet includ current pump user omnipod
rank highest term overal custom satisfact custom loyalti
like patient would stick current pump provid given opportun
switch meanwhil non-pump user indic would choos omnipod
add pump treatment plan well current market
share physician side endocrinologist spoke expect
net share taker benefit patient instal base becom
elig upgrad next year meanwhil doc forecast signific
increas pump penetr across type type patient popul go
forward technolog continu improv
pipelin offer compel opportun
competit current market expans view see
expect launch new dash mobil platform later year import upgrad
omnipod patient experi one serv foundat futur innov
pod side meanwhil believ plan transit direct european sale
forc juli potenti improv near-term profit drive faster new
patient addit time long-term label expans includ concentr insulin
formul could effect doubl omnipod address market see
horizon autom insulin deliveri system competit entri race develop
artifici pancrea
initi buy price target valu share
forward ntm sale estim impli upsid potenti current level
page analyst certif import disclosur
billerica base medic devic compani compani began
sale omnipod insulin manag system novel dispos patch pump
patient insulin-depend diabet believ omnipod uniqu design offer
varieti advantag tradit durabl insulin pump includ elimin
tube connect pump patient improv comfort increas conveni
attribut allow carv meaning posit insulin pump
market estim top world-wide revenu last year
insulet sale grown compound-annual-growth-rate sinc approach last
year estim compani ship pod global
current instal base nearli patient world-wide model call
total revenu climb compound-annual-growth-rate driven on-going share gain
 transit direct sale forc intern anticip new product
approv open type diabet market opportun
figur revenu composit million
compani report guggenheim secur llc estim
page analyst certif import disclosur
view omnipod truli differenti offer within insulin pump market
elimin tube associ tradit pump simplifi cannula insert
insulin deliveri process elimin potenti kink snag cloth allow
greater flexibl term on-bodi placement pod also waterproof
feet minut featur made particularli popular pediatr patient
meanwhil believ may real clinic benefit patch pump design
well studi journal diabet scienc technolog found insulin
deliveri omnipod predict due variat flow speed tube
system depend pump locat rel infus site
abil vari pod placement may reduc risk infus site infect scar
time
research suggest omnipod patient-friendli design earn strong
follow within diabet commun recent conduct survey type
diabet util insulin pump manag diseas within sampl
market share slightli share estim compani
hold overal insulin pump market patient basi ask respond
number question relat pump experi includ overal satisfact
level pump would choos opportun switch today
case score well earn highest custom satisfact score vs
averag competitor regist highest percentag current
custom would opt stick compani given chanc switch vs
averag competitor importantli survey includ adult patient
believ actual skew result somewhat given strong
appeal higher share posit pediatr popul
feedback non-pump point potenti futur share gain
omnipod well patient survey use insulin
pump today indic consid ad one treatment plan
ask patient product would like choos
adopt pump said would pick omnipod number
doubl current share posit view data point posit indic
compani continu captur outsiz portion new pump patient go
forward support expect on-going share gain next year
competit landscap section insight physician view omnipod
recent endocrinologist survey
page analyst certif import disclosur
figur would non-er like use
omnipod commerci avail decad believ
recent put piec place maxim potenti
patrick sullivan took ceo bolster compani sale custom
support broader
reimburs coverag began formul oper plan capabl deliv
improv product qualiti meaning profit result past three
half year impress estim compani world-wide patient
instal base grown compound-annual-growth-rate period revenu
organ basi gross margin improv last year
manag guidanc call compani alreadi score
two major reimburs win year garner medicar coverag first time
januari secur in-network statu unitedhealthcar march
meanwhil see transit direct sale forc europ potenti
catalyst growth profit standpoint omnipod
sold intern distribut agreement ypsome
estim insulet eu patient share modestli share
vs believ
focu dedic rep augment
competit near-term notic chang insulet
profit manag expect captur distributor margin result
equival asp increas transit occur juli shift
drive forc behind manag forecast overal gross margin jump
back half year
fda approv new dash mobil platform later year could enhanc
insulet competit dash replac compani legaci locked-
android smartphon featur simpl touchscreen interfac pair
app user phone and/or phone parent/caregiv new
capabl display pump cgm data singl dashboard
inform transmit secur bluetooth connect diabet space
begin defin much patient experi technolog underpin
glycem control see dash major step forward omnipod
serv platform compani futur innov follow
submiss earlier year manag target dash launch
page analyst certif import disclosur
beyond dash see label expans includ concentr insulin formul
open signific new growth opportun omnipod capac
insulin averag type patient consum per day fit
pump lifespan howev vast major type patient requir much
insulin per day prevent make signific
inroad popul date type patient account
compani current instal base put perspect estim
current insulin pump user type expect number climb
address work expand omnipod label
includ use concentr insulin formul pack two five time mani
insulin unit volum compani estim could doubl
address market patient roughli approv
formul expect project follow
figur concentr insulin market expans opportun
long-term also work keep pace race artifici
pancrea compani partner cgm compon horizon
autom glucos control system demonstr promis result earli
clinic studi horizon incorpor glucos control algorithm directli pod
allow patient stay close loop mode even rang
direct bluetooth link pod cgm sensor timelin
commerci system still somewhat air work
regulatori pathway base progress date estim horizon could
 market late earli
page analyst certif import disclosur
estim world-wide insulin pump accessori market top
grow mid- high-singl digit clip leader
space sinc acquisit minim current hold share posit
sell number pump model current flagship product recent launch
pair guardian cgm sensor form hybrid close loop system
first commerci avail system incorpor predict low glucos
suspend featur automat basal titrat throughout day signific step toward
eventu close loop artifici pancrea platform recent
resolv sensor shortag impact abil meet demand
rest sensor-aug pump portfolio expect compani enjoy strong
momentum across diabet busi next quarter
figur estim insulin revenu market share geographi
compani report guggenheim secur llc estim
remain domin leader durabl pump segment
succeed carv meaning share posit omnipod novel patch pump
design estim compani current roughli share
revenu basi global compar five year ago
respect demonstr far compani come time transit
direct sale forc europ strong momentum new patient start domest
model call share rise market posit
strong player
wasnt long ago held posit despit solid show anima
pump segment howev compani overal diabet franchis consist
underperform sale declin underli basi everi year
review strateg option busi decid octob
discontinu insulin pump sale wind anima prelud sale rest
lifescan diabet suppli franchis announc earlier year see js exit
signific opportun player roughli anima patient
world-wide market set come pump upgrad next year
 formal partner ensur transit
smooth possibl dilig suggest well posit benefit
dynam well
page analyst certif import disclosur
along type patient survey mention also recent
conduct survey high volum endocrinologist among question
ask recommend anima patient come
end pump warranti switch pump far
common respons respond indic recommend omnipod
patient patient ask pump would
like switch chose omnipod base anima field
period cycl current pump would impli potenti tailwind
new patient per year put perspect estim
compani ad roughli patient global last year
figur physician recommend anima patient
survey result suggest js exit also tailwind tandem
diabet enter insulin pump market gain solid traction
portfolio pump featur sleek user-friendli design tandem novel devic
updat may compel featur allow patient download softwar
updat home becom avail life pump rather
wait new pump get access recent advanc septemb system allow
compani begin retroact upgrad instal base slim pump
compat dexcom cgm system octob tandem announc
would make new featur approv avail free charg in-
warranti user see innov softwar architectur signific advanc
could give patient fenc purchas new pump confid
upgrad without worri miss next big product introduct
pipelin tandem target first foray autom
insulin deliveri categori addit basal iq slim pump algorithm
use data dexcom sensor adjust basal insulin deliveri throughout day
thu minim frequenc and/or shorten durat hyperglycem
hypoglycem event second iter product featur integr dexcom
sensor sophist glucos control algorithm privately-held typezero
technolog dub slim control iq expect launch control iq
would differ compet aid system like medtron titrat basal
insulin deliveri level also provid autom correct bolus respons
page analyst certif import disclosur
final roch last major competitor insulin pump market accu-check
combo system integr glucos meter accu-check aviva pump accu-
check spirit believ roch sizabl presenc europ roughli
share rel nich player prior decis exit domest
pump market end result expect see instal base wind
patient becom elig upgrad next coupl year despit
decis on-going weak core bgm busi roch appear still
interest innov diabet manag technolog compani sign
exclus distributor eversens implant cgm system
germani itali netherland agreement sinc expand
physician survey respond see compani near-
term momentum pump market tandem also pois
pick share volum weight basi group expect gain
share back launch js exit meanwhil
tandem forecast add share
overal pump penetr endocrinologist spoke bullish
potenti increas adopt next year note
group report higher pump penetr today within practic
believ reflect market broadli adopt among type patient
today vs nationwid nonetheless view forecast pump util
rise adult pediatr patient three year
encourag data point comparison model assum penetr climb
stori similar type side estim overal penetr stand
today vs respond report within insulin-intens
popul low teen estim non-intens patient physician expect
util pump among type patient practic climb
group respect compar forecast type
penetr rise insulin-intens popul estim dont current
alloc util non-intens group
page analyst certif import disclosur
model ww insulin pump revenu grow driven annual
growth patient instal base believ roughli consist recent
growth trend believ forecast could prove conserv base due dilig
wave new technolog expect come market next year
note estim non-cov compani denot base public inform factset consensu data
compani report factset guggenheim secur llc estim
page analyst certif import disclosur
million market market growth medic suppli devic
diabet global epidem accord american diabet associ
american diabet popul preval
medicare-ag popul even higher rank seventh lead caus
death nationwid cite underli caus nearli case health
burden exert tremend financi toll total cost diagnos diabet
estim includ direct medic expens
lost product global world organ estim adult
diabet figur quadrupl sinc diseas contribut
death year
diabet patient typic broken two main subgroup type diabet
suffer underli immun disord caus bodi cell target
beta cell pancrea produc insulin caus condit unknown
believ deriv combin genet environment factor type
patient usual diagnos children ada estim roughli
type patient today cure type diabet patient
requir take lifelong regimen synthet insulin inject surviv
type diabet acquir metabol disord character increas insulin
resist although pancrea continu produc insulin total beta cell output may
also depress genet factor play role determin person suscept
type diabet usual caus obes lack exercis poor dietari habit
result treatment type diabet gener begin recommend lifestyl
chang unsuccess patient progress drug therapi eventu insulin-
intens treatment estim american suffer type
diabet insulin depend
diabet number seriou health consequ without insulin bodi lose
abil regul blood sugar lead episod hyperglycemia high blood
glucos hypoglycemia low blood glucos hyperglycemia gener defin
blood glucos level mg/dl associ increas long-term risk
cardiovascular renal neurolog vision disord hypoglycemia mg/dl
acut issu brain requir continu suppli glucos function properli
earli symptom hypoglycem episod may includ dizzi confus rapid
heart rate treat lead seizur loss conscious even death
page analyst certif import disclosur
technolog effect manag diabet rapidli evolv insulin-depend
diabet must test blood sugar regularli throughout day tradit
done prick finger insert test strip drop blood self-
monitor blood glucos meter smbg read use determin insulin
dose patient usual inject multipl time day stay
within normal glucos rang challeng approach point-in-tim
blood glucos estim provid strip meter test provid inform
trend matter dilig patient use meter still obtain
small number read cours day
continu glucos monitor address shortcom smbg cgm system
use transcutan sensor test glucos level interstiti fluid skin
sensor worn bodi attach transmitt relay blood sugar
read handheld receiv and/or smartphon new read taken everi
minut throughout day provid patient near real-tim visibl
glucos level trend facilit better manag diseas
figur show exampl patient test four time cours
day two elev read two within normal rang figur
read overlaid cgm data show patient actual spent
vast major day outsid normal rang
page analyst certif import disclosur
cgm penetr still rel low today believ technolog
reach import tip point receiv fda approv first
profession cgm system provid physician three day worth
download read establish baselin prescrib therapi
follow guardian sensor dexcom st system first
devic give patient access blood glucos trend inform despit
signific interest patient physician howev technolog struggl
gain traction initi sensor accuraci prove sub-optimal payer balk foot
bill expens new devic left patient still need use tradit smbg
meter daili calibr cgm sensor insulin dose
cours past decad improv sensor technolog mount
bodi evid demonstr superior cgm smbg mean
effect control glucos level turn tide estim
number patient use cgm devic rose compound-annual-growth-rate penetr
type segment rise period januari
approv dexcom first cgm system cover medicar
pace innov pick steam last month fda approv
connect cgm system dexcom cgm system bring
new gener sensor market follow posit fda advisori panel last
week devic could soon join senseon eversens first long-term
implant cgm system technolog roll futur iter come
market believ potenti establish cgm standard care
type diabet also signific subset type popul
meanwhil insulin deliveri side long march toward artifici pancrea
also reach critic junctur insulin-depend diabet administ insulin
multipl daili inject mdi howev approach repres signific
burden patient term qualiti life may alway result accur dose
result research work year find better way
minim usher modern insulin pump market seri product launch
prior acquisit today estim
third type insulin-intens type diabet util
pump provid predict precis insulin deliveri discret form factor
better fit patient live repres meaning advanc mdi
tradit pump still requir signific interact part patient input data
determin dose
page analyst certif import disclosur
